Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of VRC07-523LS in Healthy Adults
NCT03015181Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Feb 2017
- Primary completion
- Jul 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of VRC07-523LS in human immunodeficiency virus infection (HIV) (7 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number of Subjects Reporting Systemic Reactogenicity Signs and Symptoms at 3 days, Number of Subjects Reporting Local Reactogenicity Signs and Symptoms at 7 days and 2 more. Started Feb 2017; status: completed.
02
Drugs
VRC07-523LS
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03015181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03015181.